Drugs / PF-06801591
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04171141 | Nov 2019 → Nov 2023 | colorectal adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04152018 | Nov 2019 → Dec 2024 | bile duct cancer, endometrial cancer, esophageal cancer, gastric cancer +7 | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02573259 | Feb 2016 → Nov 2020 | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, ovarian carcinoma +2 | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02616185 | Dec 2015 → Feb 2021 | prostate neoplasm | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04181788 | Mar 2020 → Mar 2022 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06089265 | Jun → Nov 2023 | hereditary fructose intolerance | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04165317 | Dec 2019 → Dec 2024 overdue | urinary bladder carcinoma | Pfizer | Active not recruiting | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06801591 | “Anti-PD1 PF-06801591” NCT04171141 ↗ |
| Action | Inhibit | “blocks its interaction with PD-1 ligands” PMID 31145415 ↗ Jul 2019 |
| Modality | Monoclonal antibody | “a humanized immunoglobulin G4 monoclonal antibody” PMID 31145415 ↗ Jul 2019 |
| Route | Subcutaneous | “subcutaneously at 300 mg every 4 weeks” PMID 34694529 ↗ Oct 2021 |
| Target | PDCD1 | “A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.” NCT04181788 ↗ |